Journal of Shanghai Jiao Tong University (Medical Science) >

2024 , Vol. 44 >Issue 3: 399 - 406

DOI: https://doi.org/10.3969/j.issn.1674-8115.2024.03.014

Review

Advances in the treatment of intracranial neoplastic lesions in children with neurofibromatosis 1

  • Meiling LIU ,
  • Yabing ZHOU ,
  • Xiaoqiang WANG
Expand
  • 1.Department of Pediatric Neurosurgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
    2.Department of Traditional Chinese Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
WANG Xiaoqiang, E-mail: wangxiaoqiang419@163.com.

Received date: 2023-11-13

  Accepted date: 2024-01-11

  Online published: 2024-03-28

Supported by

Shanghai Science and Technology Innovation Action Plan for Medical Research(20Y21900500)

Fold

Abstract

Neurofibromatosis 1 (NF1) is one of the most common autosomal dominant genetic diseases of the nervous system, which occurs predominantly in children. It is a multi-system damage caused by genetic defects that cause abnormal development of neural crest cells. The penetrance of NF1 is almost 100%, and the main clinical features are cafe-au-lait spots on the skin and multiple neurofibromas in peripheral nerves. NF1 can lead to intracranial neoplastic lesions, which can be divided into low grade tumors, high grade tumors and tumor-like lesions according to pathology. Most intracranial tumors with NF1 are low grade tumors, and optic pathway gliomas are the most universal, followed by brainstem gliomas, but other types of low grade tumors can also occur on other sites. High grade tumors are uncommon. Although tumor-like lesions/ unidentified bright objects are not tumors, they are the most widespread intracranial abnormalities with partial tumor nature in NF1 children. These neoplastic lesions can be treated by observation, surgery, chemotherapy, radiotherapy, targeted therapy, etc. The best treatment for different lesions is different, and their prognosis is also distinct. At present, the treatment of intracranial neoplastic lesions of NF1 in children is still controversial. This article reviews the characteristics and treatment progress of this disease, aiming to improve the public′s awareness of NF1 neoplastic lesions, provide professional plans of diagnosis and treatment, and finally promote the perfect neurosurgical therapy of NF1 patients.

Key words： neurofibromatosis 1 (NF1); intracranial neoplastic lesion; children; treatment

Cite this article

Meiling LIU , Yabing ZHOU , Xiaoqiang WANG . Advances in the treatment of intracranial neoplastic lesions in children with neurofibromatosis 1[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024 , 44(3) : 399 -406 . DOI: 10.3969/j.issn.1674-8115.2024.03.014

References

1 KRESAK J L, WALSH M. Neurofibromatosis: a review of NF1, NF2, and schwannomatosis[J]. J Pediatr Genet, 2016, 5(2): 98-104.
2 GUTMANN D H, FERNER R E, LISTERNICK R H, et al. Neurofibromatosis type 1[J]. Nat Rev Dis Primers, 2017, 3: 17004.
3 NIX J S, BLAKELEY J, RODRIGUEZ F J. An update on the central nervous system manifestations of neurofibromatosis type 1[J]. Acta Neuropathol, 2020, 139(4): 625-641.
4 FARAZDAGHI M K, KATOWITZ W R, AVERY R A. Current treatment of optic nerve gliomas[J]. Curr Opin Ophthalmol, 2019, 30(5): 356-363.
5 DAL BELLO S, MARTINUZZI D, TERESHKO Y, et al. The present and future of optic pathway glioma therapy[J]. Cells, 2023, 12(19): 2380.
6 SHAMJI M F, BENOIT B G. Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications[J]. Neurosurg Focus, 2007, 23(5): E3.
7 TAYLOR T, JASPAN T, MILANO G, et al. Radiological classification of optic pathway gliomas: experience of a modified functional classification system[J]. Br J Radiol, 2008, 81(970): 761-766.
8 KELLY J P, WEISS A H. Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1[J]. Neuro-oncology, 2013, 15(11): 1560-1567.
9 PACKER R J, ATER J, ALLEN J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas[J]. J Neurosurg, 1997, 86(5): 747-754.
10 FUSS M, HUG E B, SCHAEFER R A, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique[J]. Int J Radiat Oncol Biol Phys, 1999, 45(5): 1117-1126.
11 周勇, 赵曜. 视神经胶质瘤的诊断与治疗[J]. 河北医学, 2003, 9(3): 248-250.
11 ZHOU Y, ZHAO Y. Diagnosis and treatment of the optic nerve glioma [J]. Hebei Medicine, 2003, 9(3): 248-250.
12 COONEY T, YEO K K, KLINE C, et al. Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma[J]. Neurooncol Pract, 2020, 7(1): 4-10.
13 GUO Y J, PAN W W, LIU S B, et al. ERK/MAPK signalling pathway and tumorigenesis[J]. Exp Ther Med, 2020, 19(3): 1997-2007.
14 FANGUSARO J, ONAR-THOMAS A, POUSSAINT T Y, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial[J]. Lancet Oncol, 2019, 20(7): 1011-1022.
15 YAMASAKI F, TAKANO M, YONEZAWA U, et al. Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review[J]. Childs Nerv Syst, 2020, 36(3): 635-639.
16 HUA H, KONG Q B, ZHANG H Y, et al. Targeting mTOR for cancer therapy[J]. J Hematol Oncol, 2019, 12(1): 71.
17 WILSON B N, JOHN A M, HANDLER M Z, et al. Neurofibromatosis type 1: new developments in genetics and treatment[J]. J Am Acad Dermatol, 2021, 84(6): 1667-1676.
18 COSTA A A, GUTMANN D H. Brain tumors in neurofibromatosis type 1[J]. Neurooncol Adv, 2019, 1(1): vdz040.
19 GUILLAMO J S, CRéANGE A, KALIFA C, et al. Prognostic factors of CNS tumours in neurofibromatosis 1 (NF1): a retrospective study of 104 patients[J]. Brain, 2003, 126(Pt 1): 152-160.
20 BILANIUK L T, MOLLOY P T, ZIMMERMAN R A, et al. Neurofibromatosis type 1: brain stem tumours[J]. Neuroradiology, 1997, 39(9): 642-653.
21 LIU Z Y, FENG S S, LI J, et al. The survival benefits of surgical resection and adjuvant therapy for patients with brainstem glioma[J]. Front Oncol, 2021, 11: 566972.
22 GAGLIARDI F, DE DOMENICO P, SNIDER S, et al. γ knife radiosurgery as primary treatment of low-grade brainstem gliomas: a systematic review and metanalysis of current evidence and predictive factors[J]. Crit Rev Oncol Hematol, 2021, 168: 103508.
23 BYRNE S, CONNOR S, LASCELLES K, et al. Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas[J]. J Neurooncol, 2017, 133(3): 609-614.
24 Pascual-Castroviejo I, Pascual-Pascual S I, Via?o J, et al. Posterior fossa tumors in children with neurofibromatosis type 1 (NF1)[J]. Childs Nerv Syst, 2010, 26(11): 1599-1603.
25 SAIT S F, GIANTINI-LARSEN A M, TRINGALE K R, et al. Treatment of pediatric low-grade gliomas[J]. Curr Neurol Neurosci Rep, 2023, 23(4): 185-199.
26 WISOFF J H, SANFORD R A, HEIER L A, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children′s Oncology Group[J]. Neurosurgery, 2011, 68(6): 1548-1554;discussion 1554-1555.
27 SIEVERT A J, FISHER M J. Pediatric low-grade gliomas[J]. J Child Neurol, 2009, 24(11): 1397-1408.
28 FISHER B J, BAUMAN G S, LEIGHTON C E, et al. Low-grade gliomas in children: tumor volume response to radiation[J]. Neurosurg Focus, 1998, 4(4): e5.
29 WANG T J C, MEHTA M P. Low-grade glioma radiotherapy treatment and trials[J]. Neurosurg Clin N Am, 2019, 30(1): 111-118.
30 CAMPAGNE O, YEO K K, FANGUSARO J, et al. Clinical pharmacokinetics and pharmacodynamics of selumetinib[J]. Clin Pharmacokinet, 2021, 60(3): 283-303.
31 FISHER M J, BLAKELEY J O, WEISS B D, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas[J]. Neuro-oncology, 2022, 24(11): 1827-1844.
32 FRIEDRICH R E, MODEMANN M. Neurofibromatosis type 1-associated plexiform neurofibromas of the face and adjacent head regions: topography of lesions and surgical treatment data of 179 patients[J]. J Maxillofac Oral Surg, 2023, 22(3): 511-524.
33 NGUYEN R, KLUWE L, FUENSTERER C, et al. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits[J]. J Pediatr, 2011, 159(4): 652-655.e2.
34 NEEDLE M N, CNAAN A, DATTILO J, et al. Prognostic signs in the surgical management of plexiform neurofibroma: the Children′s Hospital of Philadelphia experience, 1974-1994[J]. J Pediatr, 1997, 131(5): 678-682.
35 AVERY R A, KATOWITZ J A, FISHER M J, et al. Orbital/periorbital plexiform neurofibromas in children with neurofibromatosis type 1: multidisciplinary recommendations for care[J]. Ophthalmology, 2017, 124(1): 123-132.
36 GROSS A M, WOLTERS P L, DOMBI E, et al. Selumetinib in children with inoperable plexiform neurofibromas[J]. N Engl J Med, 2020, 382(15): 1430-1442.
37 李帮涛, 张格, 庞启明, 等. 司美替尼治疗儿童1型神经纤维瘤病1例[J]. 中华儿科杂志, 2023, 61(10): 938-940.
37 LI B T, ZHANG G, PANG Q M, et al. Selumetinib in the treatment of type 1 neurofibromatosis in a child [J]. Chinese Journal of Pediatrics, 2023, 61(10): 938-940.
38 WIMMER K, ROSENBAUM T, MESSIAEN L. Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1[J]. Clin Genet, 2017, 91(4): 507-519.
39 RANALLI M, BONI A, CAROLEO A M, et al. Molecular characterization of medulloblastoma in a patient with neurofibromatosis type 1: case report and literature review[J]. Diagnostics, 2021, 11(4): 647.
40 MARTINEZ-VELEZ N, MARIGIL M, GARCíA-MOURE M, et al. δ-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models[J]. Acta Neuropathol Commun, 2019, 7(1): 64.
41 POLLACK I F, AGNIHOTRI S, BRONISCER A. Childhood brain tumors: current management, biological insights, and future directions[J]. J Neurosurg Pediatr, 2019, 23(3): 261-273.
42 POLLACK I F, BOYETT J M, YATES A J, et al. The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience[J]. Neuro Oncol, 2003, 5(3): 197-207.
43 FRIEDMAN G K, JOHNSTON J M, BAG A K, et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas[J]. N Engl J Med, 2021, 384(17): 1613-1622.
44 WANG L M, ENGLANDER Z K, MILLER M L, et al. Malignant glioma[J]. Adv Exp Med Biol, 2023, 1405: 1-30.
45 DIMARIO F J Jr, RAMSBY G, GREENSTEIN R, et al. Neurofibromatosis type 1: magnetic resonance imaging findings[J]. J Child Neurol, 1993, 8(1): 32-39.
46 LOPES FERRAZ FILHO J R, MUNIS M P, SOARES SOUZA A, et al. Unidentified bright objects on brain MRI in children as a diagnostic criterion for neurofibromatosis type 1[J]. Pediatr Radiol, 2008, 38(3): 305-310.
47 PILLAY-SMILEY N, LEACH J, LANE A, et al. Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on pediatric brain tumor consortium (PBTC)-029B[J]. Cancers, 2023, 15(7): 2109.
48 FERRAZ-FILHO J R L, JOSé DA ROCHA A, MUNIZ M P, et al. Unidentified bright objects in neurofibromatosis type 1: conventional MRI in the follow-up and correlation of microstructural lesions on diffusion tensor images[J]. Eur J Paediatr Neurol, 2012, 16(1): 42-47.
Options
Outlines

/

〈 〉